None of the patients received combined systemic therapy such as TKI or PD-1/PD-L1 because, in our healthcare system, government insurance doesn’t cover these treatments for HCC, making them unaffordable for most patients. The gene discussed is CD274; the disease is hepatocellular carcinoma.